Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research.
Fiche publication
Date publication
janvier 2019
Journal
Frontiers in psychiatry
Auteurs
Membres identifiés du Cancéropôle Est :
Pr HAFFEN Emmanuel
Tous les auteurs :
Bennabi D, Haffen E, Van Waes V
Lien Pubmed
Résumé
Vortioxetine has already shown its efficacy in the acute and long-term treatment of major depressive disorder (MDD) and its potential interest in the prevention of relapse. The aim of this study was to review the current status of knowledge regarding its cognitive effects. We conducted a review of key data obtained from preclinical behavioral models and clinical trials in MDD focusing on vortioxetine-induced cognitive changes. In animals, acute and chronic administration of vortioxetine improves performance on objective measures that cover a broad range of cognitive domains. In human, vortioxetine appears to be a useful treatment option in MDD patients with cognitive dysfunction. Vortioxetine constitutes a promising treatment for treatment of cognitive impairment in MDD, but its place in the therapeutic armamentarium still needs to be determined.
Mots clés
animals, cognition, humans, major depressive disorder, vortioxetine
Référence
Front Psychiatry. 2019 ;10:771